Novartis Aktie
Kursziele der Novartis-Aktie in CHF
Diese Analysten bewerten die Novartis-Aktie
| Analyst | Kursziel | Abstand Kursziel | Datum | |
|---|---|---|---|---|
| Bernstein Research | 127,08 CHF | -5,02% | 29.10.2026 | |
| JP Morgan Chase & Co. | 145,00 CHF | +8,37% | 29.10.2026 | |
| UBS AG | 130,00 CHF | -2,84% | 28.10.2026 | |
| Deutsche Bank AG | 120,00 CHF | -10,31% | 28.10.2026 | |
| RBC Capital Markets | 130,00 CHF | -2,84% | 28.10.2026 | |
| Jefferies & Company Inc. | 110,00 CHF | -17,79% | 27.10.2026 | |
| Barclays Capital | 125,00 CHF | -6,58% | 26.10.2026 | |
| Goldman Sachs Group Inc. | 113,00 CHF | -15,55% | 01.10.2026 | |
| Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | 105,00 CHF | -21,52% | 11.09.2026 | |
| DZ BANK | - | - | 22.07.2026 |
Kursziele im Branchenvergleich
| Aktie | Buy | Hold | Sell | Ø Kursziel | Abst. Kursziel |
|---|---|---|---|---|---|
| Abbott Laboratories | 0 | 0 | 0 | - | - |
| Alexion Pharmaceuticals Inc. | 0 | 0 | 0 | - | - |
| Allergan Inc. | 0 | 0 | 0 | - | - |
| APONTIS PHARMA | 0 | 0 | 0 | - | - |
| AstraZeneca PLC | 9 | 1 | 0 | 157,78 GBP | - |
| Bayer | 7 | 2 | 0 | 56,56 EUR | +13,53% |
| Celgene Corp. | 0 | 0 | 0 | - | - |
| EVOTEC SE | 1 | 2 | 0 | 5,70 EUR | +95,61% |
| Gilead Sciences Inc. | 0 | 0 | 0 | - | - |
| GSK PLC Registered Shs | 2 | 6 | 2 | 20,63 GBP | +11,15% |
| Johnson & Johnson | 0 | 0 | 0 | - | - |
| Merck Co. | 0 | 0 | 0 | - | - |
| Merck KGaA | 3 | 5 | 0 | 149,00 EUR | -1,46% |
| Mylan N.V. | 0 | 0 | 0 | - | - |
| Novartis AG | 1 | 8 | 1 | 122,79 CHF | -8,23% |
| Pfizer Inc. | 2 | 5 | 1 | 27,71 USD | -7,48% |
| Roche Holding AG (Inhaberaktie) | 0 | 0 | 0 | - | - |
| Roche Holding AG Inhaber-Partizipationsschein | 5 | 3 | 1 | 378,56 CHF | -6,13% |
| Sanofi S.A. | 5 | 5 | 0 | 90,13 EUR | +12,96% |
| STADA | 0 | 0 | 0 | - | - |
| Teva Pharmaceutical Industries Ltd. (spons. ADRs) | 0 | 0 | 0 | - | - |
| Vertex Pharmaceuticals Inc. | 0 | 0 | 0 | - | - |
| Warner Chilcott plc | 0 | 0 | 0 | - | - |